For decades, the Chromium Release Assay (CRA) has been considered the gold standard for measuring Natural Killer (NK) cell-mediated lysis of tumor cells, or of antibody-coated target cells in antibody-dependent, cell-mediated cytotoxicity (ADCC). Until now, the CRA has been deemed to be unparalleled in sensitivity. No longer!
The CTL non-radioactive Target cell Visualization Assay (TVA™) not only has the same sensitivity as CRA, but can also measure the lysis of up to three different target cells simultaneously and be performed in Terasaki plate format, thereby reducing the number of effector cells needed by 30-fold. The TVA™ Platform is based on direct, single-cell imaging, is less laborious than CRA, and has fully-automated analysis and data reporting. Streamlined quality control and tamper-proof audit trails facilitate the workflow in regulated clinical laboratories.
PRODUCTS / SERVICES